Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-02-06 Sale | 2025-02-06 3:59 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 124,438 | $0 | $0 | 0 (Direct) | View |
| 2024-03-18 Sale | 2024-03-19 6:44 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 9,361 | $5.0426 | $47,204 | 192,666 (Direct) | View |
| 2023-07-03 Sale | 2023-07-05 9:11 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,701 | $25.04 | $42,593 | 79,896 (Direct) | View |
| 2023-06-01 Sale | 2023-06-05 6:06 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,201 | $30.64 | $98,070 | 80,828 (Direct) | View |
| 2023-05-15 Sale | 2023-05-16 8:29 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 21,401 | $34.55 | $739,338 | 84,029 (Direct) | View |
| 2023-05-01 Sale | 2023-05-02 4:01 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,201 | $31.7 | $101,472 | 63,081 (Direct) | View |
| 2023-04-03 Sale | 2023-04-04 4:24 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,201 | $32.15 | $102,912 | 66,282 (Direct) | View |
| 2023-03-09 Sale | 2023-03-09 9:46 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 18,517 | $31.59 | $584,884 | 73,222 (Direct) | View |
| 2023-03-01 Sale | 2023-03-02 9:25 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,201 | $33.5 | $107,234 | 49,390 (Direct) | View |
| 2023-02-01 Sale | 2023-02-02 9:38 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,201 | $34.6 | $110,755 | 105,111 (Direct) | View |
| 2023-01-20 Sale | 2023-01-23 5:35 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,000 | $31 | $31,000 | 57,877 (Direct) | View |
| 2023-01-09 Sale | 2023-01-10 8:06 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,701 | $27.16 | $100,525 | 58,877 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-03-10 Option Award | 2025-03-11 4:30 pm | N/A 2035-03-09 | Crinetics Pharmaceuticals Inc. | CRNX | Schilke Tobin Chief Financial Officer | 132,000 | $0 | 132,000 (Direct) | View |
| 2025-02-04 Equity Swap | 2025-02-06 3:59 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 97,999 | $3.65 | 0 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-06 3:59 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 20,883 | $0 | 0 (Direct) | View |
| 2025-02-03 Option Award | 2025-02-05 7:53 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 6,888 | $0 | 201,554 (Direct) | View |
| 2024-12-31 Option Award | 2025-01-03 4:34 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,000 | $2.1845 | 194,666 (Direct) | View |
| 2024-06-30 Option Award | 2024-07-02 5:47 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,000 | $2.1845 | 193,666 (Direct) | View |
| 2024-03-15 Tax Withholding | 2024-03-19 6:44 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,822 | $5.305 | 192,666 (Direct) | View |
| 2024-02-29 Option Award | 2024-03-04 4:44 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 17,447 | $0 | 205,849 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 4:46 pm | 2025-02-15 2028-01-31 | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 241,668 | $0 | 333,403 (Direct) | View |
| 2023-12-31 Option Award | 2024-01-03 4:48 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 434 | $7.47 | 91,735 (Direct) | View |
| 2023-08-11 Tax Withholding | 2023-08-15 4:16 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 11,215 | $18.91 | 91,301 (Direct) | View |
| 2023-08-11 Option Award | 2023-08-15 4:16 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 22,620 | $0 | 91,301 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 9:11 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 769 | $15.61 | 79,896 (Direct) | View |
| 2022-02-02 Option Award | 2023-05-16 8:29 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 42,349 | $0 | 84,029 (Direct) | View |
| 2023-03-15 Tax Withholding | 2023-03-17 3:21 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,739 | $30.65 | 69,483 (Direct) | View |
| 2022-09-22 Option Award | 2023-03-09 9:46 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 42,349 | $0 | 73,222 (Direct) | View |
| 2023-02-15 Tax Withholding | 2023-02-16 8:28 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 2,085 | $33.21 | 52,591 (Direct) | View |
| 2023-01-31 Option Award | 2023-02-02 9:38 pm | N/A 2033-01-30 | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 50,435 | $0 | 105,111 (Direct) | View |
| 2022-12-31 Option Award | 2023-01-03 4:29 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 645 | $12.18 | 62,578 (Direct) | View |
| 2022-12-15 Tax Withholding | 2022-12-16 4:12 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,557 | $21.5 | 61,933 (Direct) | View |
| 2022-06-30 Option Award | 2022-07-05 6:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 965 | $11.75 | 63,490 (Direct) | View |
| 2022-03-15 Tax Withholding | 2022-03-17 5:48 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin Chief Financial Officer | 2,607 | $15.79 | 62,525 (Direct) | View |
| 2022-02-15 Tax Withholding | 2022-02-17 8:49 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 2,924 | $13.35 | 65,132 (Direct) | View |
| 2022-02-02 Option Award | 2022-02-04 8:31 pm | N/A 2032-02-01 | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 68,093 | $0 | 68,093 (Direct) | View |
| 2021-12-31 Other | 2022-01-04 8:58 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 404 | $13.87 | 68,460 (Direct) | View |
| 2021-12-15 Tax Withholding | 2021-12-17 5:31 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,556 | $15.92 | 67,652 (Direct) | View |
| 2021-06-30 Other | 2021-07-02 7:53 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 446 | $24.09 | 69,654 (Direct) | View |
| 2021-02-15 Tax Withholding | 2021-02-19 8:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 2,657 | $28.97 | 68,762 (Direct) | View |
| 2021-02-02 Option Award | 2021-02-04 9:15 pm | N/A 2031-02-01 | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 63,545 | $0 | 112,344 (Direct) | View |
| 2020-12-31 Other | 2021-01-04 8:02 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 493 | $21.36 | 49,292 (Direct) | View |
| 2020-12-15 Tax Withholding | 2020-12-22 8:39 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,556 | $26.75 | 48,306 (Direct) | View |
| 2020-09-30 Tax Withholding | 2020-10-02 8:32 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 5,446 | $25.14 | 49,862 (Direct) | View |
| 2020-09-30 Option Award | 2020-10-02 8:32 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 15,750 | $0 | 49,862 (Direct) | View |